Madrigal Pharmaceuticals, Inc. SEC filings MDGL
Madrigal Pharmaceuticals, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Nov 12, 2010. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 17, 2026 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 20, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 25, 2024 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 21, 2023 | — |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEF 14A | Proxy statement | May 2, 2022 | Jun 15, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 17, 2021 |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 17, 2020 |
| DEFA14A | Additional proxy material | May 15, 2019 | — |
| DEF 14A | Proxy statement | May 15, 2019 | Jun 27, 2019 |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 19, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 29, 2017 |
| DEFA14A | Additional proxy material | Jul 6, 2016 | — |
| DEFA14A | Additional proxy material | Jun 14, 2016 | — |
| DEFA14A | Additional proxy material | Jun 8, 2016 | — |
| DEFM14A | Filing | Jun 8, 2016 | — |
| DEFA14A | Additional proxy material | Jun 2, 2016 | — |
| PREM14A | Filing | May 19, 2016 | Jun 1, 2016 |
| DEFA14A | Additional proxy material | May 3, 2016 | — |
| DEFA14A | Additional proxy material | Apr 15, 2016 | — |
| DEFA14A | Additional proxy material | Apr 14, 2016 | — |
| DEFA14A | Additional proxy material | Apr 14, 2016 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 11, 2015 |
| DEF 14A | Proxy statement | Apr 30, 2014 | Jun 12, 2014 |
| DEF 14A | Proxy statement | Apr 29, 2013 | Jun 13, 2013 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2013 | Jun 13, 2013 |
| DEF 14A | Proxy statement | Apr 27, 2012 | Jun 14, 2012 |
| DEF 14A | Proxy statement | Apr 29, 2011 | Jun 2, 2011 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDGL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- West Conshohocken, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1157601
- Former names
- MADRIGAL PHARMACEUTICALS, INC. (until Nov 3, 2026); SYNTA PHARMACEUTICALS CORP (until Aug 1, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.